Details of the Drug

General Information of Drug (ID: DM4YMIS)

Drug Name

Aldesleukin

Synonyms

Proleukin (TN)

Indication

Disease Entry	ICD 11	Status	REF
Renal cell carcinoma	2C90	Approved	[1]
Non-hodgkin lymphoma	2B33.5	Phase 2	[1]

Therapeutic Class

Anticancer Agents

Sequence

MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL
EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN
RWITFCQSIISTLT

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 13 - 85 minutes [2]
Vd: The volume of distribution (Vd) of drug is 0.18 L/kg [3]

Cross-matching ID

DrugBank ID: DB00041
TTD ID: D05PUD

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-2 (IL2)	TTF89GD	IL2_HUMAN	Modulator	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Renal cell carcinoma

ICD Disease Classification

2C90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-2 (IL2)	DTT	IL2	7.64E-01	1.04E-02	0.07

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Aldesleukin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Aldesleukin caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[15]
-----------

Coadministration of a Drug Treating the Disease Different from Aldesleukin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[16]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Thioguanine.	Acute myeloid leukaemia [2A60]	[17]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Oliceridine.	Acute pain [MG31]	[18]
Chlorzoxazone	DMCYVDT	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Chlorzoxazone.	Acute pain [MG31]	[18]
Mepyramine	DMB4SFH	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Aldesleukin and Inotersen.	Amyloidosis [5D00]	[20]
Marinol	DM70IK5	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Marinol.	Anorexia nervosa [6B80]	[18]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[21]
Lorazepam	DM84ZXF	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Lorazepam.	Anxiety disorder [6B00-6B0Z]	[18]
Butalbital	DM9J04X	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Butalbital.	Anxiety disorder [6B00-6B0Z]	[18]
Buspirone	DMBS632	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Buspirone.	Anxiety disorder [6B00-6B0Z]	[18]
Clorazepate	DMC3JST	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Clorazepate.	Anxiety disorder [6B00-6B0Z]	[19]
Alprazolam	DMC7XDN	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Alprazolam.	Anxiety disorder [6B00-6B0Z]	[18]
Methylphenobarbital	DMDSWAG	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[19]
Hydroxyzine	DMF8Y74	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[18]
Halazepam	DMPFWO6	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Halazepam.	Anxiety disorder [6B00-6B0Z]	[18]
Chlordiazepoxide	DMTN5XI	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Chlordiazepoxide.	Anxiety disorder [6B00-6B0Z]	[18]
Chlormezanone	DMTWUXR	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[18]
Clobazam - Lundbeck	DMW1OQ0	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Clobazam - Lundbeck.	Anxiety disorder [6B00-6B0Z]	[18]
Oxazepam	DMXNZM4	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[18]
Promazine	DMZAL7W	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Promazine.	Appearance/behaviour symptom [MB23]	[18]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Aldesleukin and Roflumilast.	Asthma [CA23]	[20]
Desipramine	DMT2FDC	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[18]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[22]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Linezolid.	Bacterial infection [1A00-1C4Z]	[23]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
ABT-492	DMJFD2I	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[22]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Moxifloxacin	DMU8V4S	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Moxifloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Aldesleukin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[24]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[22]
Secobarbital	DM14RF5	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Secobarbital.	Chronic insomnia [7A00]	[18]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Dihydrocodeine.	Chronic pain [MG30]	[19]
Morphine	DMRMS0L	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Morphine.	Chronic pain [MG30]	[18]
Methohexital	DM7YMIT	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Methohexital.	Corneal disease [9A76-9A78]	[18]
Thiopental	DMGP8AX	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Thiopental.	Corneal disease [9A76-9A78]	[18]
Alfentanil	DMVO0UB	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Alfentanil.	Corneal disease [9A76-9A78]	[18]
Remifentanil	DMZTXCH	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Remifentanil.	Corneal disease [9A76-9A78]	[18]
Methadone	DMTW6IU	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Methadone.	Cough [MD12]	[18]
Cidofovir	DMA13GD	Major	Increased risk of nephrotoxicity by the combination of Aldesleukin and Cidofovir.	Cytomegaloviral disease [1D82]	[25]
Sertraline	DM0FB1J	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Sertraline.	Depression [6A70-6A7Z]	[18]
Trimipramine	DM1SC8M	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Trimipramine.	Depression [6A70-6A7Z]	[18]
Cyclobenzaprine	DM1YBRM	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Cyclobenzaprine.	Depression [6A70-6A7Z]	[18]
Fluoxetine	DM3PD2C	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Fluoxetine.	Depression [6A70-6A7Z]	[18]
Nortriptyline	DM4KDYJ	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Nortriptyline.	Depression [6A70-6A7Z]	[18]
Vilazodone	DM4LECQ	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Vilazodone.	Depression [6A70-6A7Z]	[18]
Nefazodone	DM4ZS8M	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Nefazodone.	Depression [6A70-6A7Z]	[18]
Paroxetine	DM5PVQE	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Paroxetine.	Depression [6A70-6A7Z]	[18]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Selegiline.	Depression [6A70-6A7Z]	[23]
Duloxetine	DM9BI7M	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Duloxetine.	Depression [6A70-6A7Z]	[18]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Isocarboxazid.	Depression [6A70-6A7Z]	[23]
Milnacipran	DMBFE74	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Milnacipran.	Depression [6A70-6A7Z]	[18]
Escitalopram	DMFK9HG	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Escitalopram.	Depression [6A70-6A7Z]	[18]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Tranylcypromine.	Depression [6A70-6A7Z]	[23]
Desvenlafaxine	DMHD4PE	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Desvenlafaxine.	Depression [6A70-6A7Z]	[18]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Phenelzine.	Depression [6A70-6A7Z]	[23]
Clomipramine	DMINRKW	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Clomipramine.	Depression [6A70-6A7Z]	[18]
Trazodone	DMK1GBJ	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Trazodone.	Depression [6A70-6A7Z]	[18]
Amitriptyline	DMK7F9S	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Amitriptyline.	Depression [6A70-6A7Z]	[18]
Amoxapine	DMKITQE	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Amoxapine.	Depression [6A70-6A7Z]	[18]
Mirtazapine	DML53ZJ	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Mirtazapine.	Depression [6A70-6A7Z]	[18]
Protriptyline	DMNHTZI	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Protriptyline.	Depression [6A70-6A7Z]	[18]
Doxepin	DMPI98T	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Doxepin.	Depression [6A70-6A7Z]	[18]
Maprotiline	DMPWB7T	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Maprotiline.	Depression [6A70-6A7Z]	[18]
Fluvoxamine	DMQTJSX	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Fluvoxamine.	Depression [6A70-6A7Z]	[18]
Venlafaxine	DMR6QH0	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Venlafaxine.	Depression [6A70-6A7Z]	[18]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Esketamine.	Depression [6A70-6A7Z]	[18]
PMID27977313-Compound-29	DMIF7KG	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and PMID27977313-Compound-29.	Discovery agent [N.A.]	[26]
Citalopram derivative 1	DMITX1G	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Citalopram derivative 1.	Discovery agent [N.A.]	[18]
Heroin diacetylmorphine	DMDBWHY	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[19]
Meclizine	DMS7T13	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Meclizine.	Dizziness and giddiness [MB48]	[18]
Diazepam	DM08E9O	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[18]
Primidone	DM0WX6I	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Primidone.	Epilepsy/seizure [8A61-8A6Z]	[18]
Cenobamate	DMGOVHA	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Cenobamate.	Epilepsy/seizure [8A61-8A6Z]	[18]
Clonazepam	DMTO13J	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[18]
Phenobarbital	DMXZOCG	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[18]
Cannabidiol	DM0659E	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Cannabidiol.	Epileptic encephalopathy [8A62]	[18]
Diphenhydramine	DMKQTBA	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[18]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Procarbazine.	Hodgkin lymphoma [2B30]	[23]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[27]
Indinavir	DM0T3YH	Moderate	Decreased metabolism of Aldesleukin caused by Indinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Aldesleukin caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Aldesleukin caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Aldesleukin caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Aldesleukin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[30]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Aldesleukin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[31]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Aldesleukin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[32]
Temazepam	DM02A65	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Temazepam.	Insomnia [7A00-7A0Z]	[18]
Suvorexant	DM0E6S3	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Suvorexant.	Insomnia [7A00-7A0Z]	[18]
Amobarbital	DM0GQ8N	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Amobarbital.	Insomnia [7A00-7A0Z]	[18]
Ethchlorvynol	DM53IP1	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Ethchlorvynol.	Insomnia [7A00-7A0Z]	[18]
Ramelteon	DM7IW9J	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Ramelteon.	Insomnia [7A00-7A0Z]	[18]
Eszopiclone	DM8RZ9H	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Eszopiclone.	Insomnia [7A00-7A0Z]	[18]
Flurazepam	DMAL4G0	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Flurazepam.	Insomnia [7A00-7A0Z]	[18]
Butabarbital	DMC5AST	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Butabarbital.	Insomnia [7A00-7A0Z]	[18]
Triazolam	DMETYK5	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Triazolam.	Insomnia [7A00-7A0Z]	[18]
Pentobarbital	DMFNH7L	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Pentobarbital.	Insomnia [7A00-7A0Z]	[18]
Zaleplon	DMGFWSM	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Zaleplon.	Insomnia [7A00-7A0Z]	[18]
Propiomazine	DMKY8V1	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Propiomazine.	Insomnia [7A00-7A0Z]	[18]
Tasimelteon	DMLOQ1V	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Tasimelteon.	Insomnia [7A00-7A0Z]	[18]
Paraldehyde	DMOC1BX	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Paraldehyde.	Insomnia [7A00-7A0Z]	[18]
Nabilone	DMVRYT2	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Nabilone.	Insomnia [7A00-7A0Z]	[18]
Quazepam	DMY4D87	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Quazepam.	Insomnia [7A00-7A0Z]	[18]
Estazolam	DMZGXUM	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Estazolam.	Insomnia [7A00-7A0Z]	[18]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Aldesleukin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[33]
Remimazolam	DMLVSYX	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[18]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Methotrexate.	Leukaemia [2A60-2B33]	[20]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Aldesleukin and Denosumab.	Low bone mass disorder [FB83]	[34]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Aldesleukin and Porfimer Sodium.	Lung cancer [2C25]	[35]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Aldesleukin caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[36]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Aldesleukin caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[26]
Cladribine	DM3JDRP	Major	Additive immunosuppressive effects by the combination of Aldesleukin and Cladribine.	Mature B-cell leukaemia [2A82]	[20]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Idelalisib.	Mature B-cell leukaemia [2A82]	[38]
Alemtuzumab	DMZL3IV	Moderate	Additive immunosuppressive effects by the combination of Aldesleukin and Alemtuzumab.	Mature B-cell leukaemia [2A82]	[39]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Clofarabine.	Mature B-cell lymphoma [2A85]	[40]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[41]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Aldesleukin caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[42]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Lasmiditan.	Migraine [8A80]	[43]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Flibanserin.	Mood disorder [6A60-6E23]	[18]
Dexmedetomidine	DM93L4X	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Dexmedetomidine.	Mood/affect symptom [MB24]	[18]
Midazolam	DMXOELT	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Midazolam.	Mood/affect symptom [MB24]	[18]
Doxylamine	DMKOXFE	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Doxylamine.	Morning sickness disorder [SC00]	[18]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Aldesleukin and Thalidomide.	Multiple myeloma [2A83]	[44]
Baclofen	DM0QV1J	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Baclofen.	Multiple sclerosis [8A40]	[18]
Interferon beta-1a	DM1A6RV	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Interferon beta-1a.	Multiple sclerosis [8A40]	[45]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Aldesleukin and Siponimod.	Multiple sclerosis [8A40]	[16]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Aldesleukin and Fingolimod.	Multiple sclerosis [8A40]	[46]
Interferon beta-1b	DMCN61Z	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Interferon beta-1b.	Multiple sclerosis [8A40]	[45]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Ozanimod.	Multiple sclerosis [8A40]	[23]
Carisoprodol	DMWR1JC	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Carisoprodol.	Musculoskeletal disorder [FA00-FC0Z]	[18]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Aldesleukin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[47]
Droperidol	DM0DXA8	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Droperidol.	Nausea/vomiting [MD90]	[18]
Prochlorperazine	DM53SRA	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Prochlorperazine.	Nausea/vomiting [MD90]	[18]
Promethazine	DM6I5GR	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Promethazine.	Nausea/vomiting [MD90]	[18]
Cyclizine	DM9G7BS	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Cyclizine.	Nausea/vomiting [MD90]	[18]
Thiethylperazine	DMU3IET	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Thiethylperazine.	Nausea/vomiting [MD90]	[18]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Aldesleukin and Bupropion.	Nicotine use disorder [6C4A]	[48]
Levomethadyl Acetate	DM06HG5	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[19]
Pentazocine	DM1XBHS	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Pentazocine.	Pain [MG30-MG3Z]	[18]
Dextropropoxyphene	DM23HCX	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Dextropropoxyphene.	Pain [MG30-MG3Z]	[19]
Butorphanol	DM5KYPJ	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Butorphanol.	Pain [MG30-MG3Z]	[18]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Oxymorphone.	Pain [MG30-MG3Z]	[18]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Levorphanol.	Pain [MG30-MG3Z]	[18]
Hydromorphone	DMHP21E	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Hydromorphone.	Pain [MG30-MG3Z]	[18]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Dezocine.	Pain [MG30-MG3Z]	[18]
Codeine	DMJX6ZG	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Codeine.	Pain [MG30-MG3Z]	[18]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Nalbuphine.	Pain [MG30-MG3Z]	[18]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Buprenorphine.	Pain [MG30-MG3Z]	[18]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Hydrocodone.	Pain [MG30-MG3Z]	[18]
Tramadol	DMRQD04	Major	Increased risk of lowers seizure threshold by the combination of Aldesleukin and Tramadol.	Pain [MG30-MG3Z]	[49]
Meperidine	DMX4GND	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Meperidine.	Pain [MG30-MG3Z]	[18]
Oxycodone	DMXLKHV	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Oxycodone.	Pain [MG30-MG3Z]	[18]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Safinamide.	Parkinsonism [8A00]	[23]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Aldesleukin and Rasagiline.	Parkinsonism [8A00]	[23]
Orphenadrine	DMW542E	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Orphenadrine.	Parkinsonism [8A00]	[18]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Aldesleukin and Lindane.	Pediculosis [1G00]	[50]
Efalizumab	DMCKL5V	Moderate	Additive immunosuppressive effects by the combination of Aldesleukin and Efalizumab.	Psoriasis [EA90]	[51]
Infliximab	DMH7OIA	Major	Additive immunosuppressive effects by the combination of Aldesleukin and Infliximab.	Psoriasis [EA90]	[52]
Levomepromazine	DMIKFEL	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[18]
Triflupromazine	DMKFQJP	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Triflupromazine.	Psychotic disorder [6A20-6A25]	[18]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[22]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Aldesleukin and Canakinumab.	Rheumatoid arthritis [FA20]	[53]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Aldesleukin and Rilonacept.	Rheumatoid arthritis [FA20]	[53]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Aldesleukin and Golimumab.	Rheumatoid arthritis [FA20]	[52]
Adalimumab	DMQMV1B	Major	Additive immunosuppressive effects by the combination of Aldesleukin and Adalimumab.	Rheumatoid arthritis [FA20]	[52]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Aldesleukin and Leflunomide.	Rheumatoid arthritis [FA20]	[31]
Mesoridazine	DM2ZGAN	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Mesoridazine.	Schizophrenia [6A20]	[18]
Thioridazine	DM35M8J	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Thioridazine.	Schizophrenia [6A20]	[18]
Iloperidone	DM6AUFY	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Iloperidone.	Schizophrenia [6A20]	[18]
Paliperidone	DM7NPJS	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Paliperidone.	Schizophrenia [6A20]	[18]
Haloperidol	DM96SE0	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Haloperidol.	Schizophrenia [6A20]	[18]
Perphenazine	DMA4MRX	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Perphenazine.	Schizophrenia [6A20]	[18]
Chlorpromazine	DMBGZI3	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Chlorpromazine.	Schizophrenia [6A20]	[18]
Thiothixene	DMDINC4	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Thiothixene.	Schizophrenia [6A20]	[18]
Trifluoperazine	DMKBYWI	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Trifluoperazine.	Schizophrenia [6A20]	[18]
Risperidone	DMN6DXL	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Risperidone.	Schizophrenia [6A20]	[18]
Fentanyl	DM8WAHT	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Fentanyl.	Sensation disturbance [MB40]	[18]
Sufentanil	DMU7YEL	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Sufentanil.	Sensation disturbance [MB40]	[18]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Aldesleukin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[54]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Aldesleukin and Naltrexone.	Substance abuse [6C40]	[55]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Aldesleukin and Azathioprine.	Transplant rejection [NE84]	[16]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[22]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[22]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[22]
Methdilazine	DMAUHQX	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[18]
Trimeprazine	DMEMV9D	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[19]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Aldesleukin and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[18]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Aldesleukin and Ganciclovir.	Virus infection [1A24-1D9Z]	[16]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Aldesleukin and Valganciclovir.	Virus infection [1A24-1D9Z]	[16]
-----------


⏷ Show the Full List of 197 DDI Information of This Drug

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
6	The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
7	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
8	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
9	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
10	J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
11	Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
12	Clinical pipeline report, company report or official report of Immunservice.
13	National Cancer Institute Drug Dictionary (drug id 665656).
14	Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7.
15	Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
16	Cerner Multum, Inc. "Australian Product Information.".
17	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
18	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
19	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
22	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
23	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
24	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
25	Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA.
26	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
27	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
28	Piscitelli SC, Vogel S, Figg WD, et al. "Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus." Pharmacotherapy 18 (1998): 1212-6. [PMID: 9855318]
29	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
30	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
31	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
32	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
33	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
34	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
35	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
36	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
37	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
38	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
39	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
40	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
41	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
42	Canadian Pharmacists Association.
43	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
44	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
45	Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
46	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
47	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
48	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
49	Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
50	Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
51	Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
52	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
53	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
54	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
55	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.